SXTC
NASDAQChina SXT Pharmaceuticals Inc.
Price$2.10-0.02 (-0.71%)
02:00 PM02:15 PM
News · 26 weeks14+100%
2025-10-262026-04-19
Mix490d
- Other2(50%)
- SEC Filings2(50%)
Latest news
25 items- SECSEC Form 424B5 filed by China SXT Pharmaceuticals Inc.424B5 - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form 6-K filed by China SXT Pharmaceuticals Inc.6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- PRChina SXT Pharmaceuticals, Inc. Announces Share Re-classificationTAIZHOU, China, March 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (NASDAQ:SXTC) (the "Company" or "SXTC"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that upon the market opening on March 24, 2026, the Company's Class A Ordinary Shares will be traded on The Nasdaq Stock Market under the symbol "SXTC". On July 28, 2025, the Company held a special meeting of shareholders (the "Meeting"). At the Meeting
- PRChina SXT Pharmaceuticals, Inc. Announces Share ConsolidationTAIZHOU, China, Jan. 30, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (NASDAQ:SXTC) (the "Company" or "SXTC"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that it will effect a share consolidation of its ordinary shares at a ratio of 1-for-150, effective on February 3, 2026 (the "Share Consolidation"). The Company's Class A ordinary shares are expected to begin trading on a post-consolidation basis at the o
- PRCHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAINTAIZHOU, China, Jan. 15, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced as part of its Artificial Intelligence (AI) Insight Initiative to explore the application of Artificial Intelligence (AI) and related digital technologies across the Traditional Chinese Medicine (TCM) raw-material supply chain. This initiative is pa
- PRUnivest Securities, LLC Announces Closing of $10 Million Registered Direct Offering for its Client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)New York, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the "Offering") of approximately $10 million for its client China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) (the "Company" or "China SXT"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS")
- SECSEC Form 6-K filed by China SXT Pharmaceuticals Inc.6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form 424B5 filed by China SXT Pharmaceuticals Inc.424B5 - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- PRChina SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct OfferingTAIZHOU, China, Jan. 09, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals Inc. (NASDAQ:SXTC) (the "Company"), today announced that it has entered into a definitive agreement with a single investor for the purchase and sale of an aggregate of 66,666,666 Class A ordinary shares of the company, no par value per share (the "Shares") (or pre-funded warrants in lieu thereof), at a purchase price of $0.15 per share in a registered direct offering. The purchase price for each pre-funded warrant is identical to the purchase price for each Share, less the exercise price of $0.001 per share. The aggregate gross proceeds to the Company of this offering are expected to be approximately $10 million
- PRCHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC AI INSIGHTS INITIATIVE TO OPTIMIZE TRADITIONAL CHINESE MEDICINE PORTFOLIO, ENHANCE MARKET ANALYSIS AND EXPLORE AI-SUPPORTED CLINIC DEPLOYMENTTAIZHOU, China, Jan. 08, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced the launch of a Strategic Artificial Intelligence (AI) Insights Initiative. This initiative aims to integrate AI-driven analytics into the Company's product portfolio planning and market intelligence processes, further strengthening its long-term str
- SECSEC Form 6-K filed by China SXT Pharmaceuticals Inc.6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form EFFECT filed by China SXT Pharmaceuticals Inc.EFFECT - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form F-3 filed by China SXT Pharmaceuticals Inc.F-3 - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form POS AM filed by China SXT Pharmaceuticals Inc.POS AM - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form 20-F filed by China SXT Pharmaceuticals Inc.20-F - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form 6-K filed by China SXT Pharmaceuticals Inc.6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form 6-K filed by China SXT Pharmaceuticals Inc.6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form 6-K filed by China SXT Pharmaceuticals Inc.6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form 424B5 filed by China SXT Pharmaceuticals Inc.424B5 - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form 6-K filed by China SXT Pharmaceuticals Inc.6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form 424B5 filed by China SXT Pharmaceuticals Inc.424B5 - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form S-8 filed by China SXT Pharmaceuticals Inc.S-8 - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form 6-K filed by China SXT Pharmaceuticals Inc.6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- SECSEC Form 6-K filed by China SXT Pharmaceuticals Inc.6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
- PRChina SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price DeficiencyTAIZHOU, China, March 17, 2025 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) (the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that the Company received a written notification (the "Compliance Notice") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") dated March 13, 2025, informing the Company that it has regained compliance with the Nasdaq Listing Ru